"FDA Approves Amgen's Kyprolis as a Second-Line Multiple Myeloma Treatment" at 12:55 p.m. ET incorrectly suggested that drug was approved under an accelerated process.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amgen Charts.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amgen Charts.